Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex | NASDAQ | Salute | Ricerca medica e biotecnologica | 115,58 Mrd USD | -241,4x | 2,19 | 448,01 USD | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 16,4% Rialzo | Fai l’upgrade a Pro+ | |
Regeneron Pharma | NASDAQ | Salute | Ricerca medica e biotecnologica | 80,25 Mrd USD | 17,2x | 1,14 | 746,45 USD | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Lonza Group AG | OTC Markets | Salute | Ricerca medica e biotecnologica | 42,28 Mrd USD | 67,6x | -1,34 | 58,47 USD | 0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 22,6% Rialzo | Fai l’upgrade a Pro+ | |
argenx ADR | NASDAQ | Salute | Ricerca medica e biotecnologica | 35,27 Mrd USD | -863,4x | -10,07 | 581,92 USD | 1,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 13,4% Rialzo | Fai l’upgrade a Pro+ | |
IQVIA Holdings | NYSE | Salute | Ricerca medica e biotecnologica | 34,83 Mrd USD | 24,9x | 0,89 | 192,12 USD | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 35,9% Rialzo | Fai l’upgrade a Pro+ | |
BioNTech | NASDAQ | Salute | Ricerca medica e biotecnologica | 24,50 Mrd USD | -50,1x | 0,42 | 102,45 USD | -3,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 24,8% Rialzo | Fai l’upgrade a Pro+ | |
BeiGene ADS | NASDAQ | Salute | Ricerca medica e biotecnologica | 19,95 Mrd USD | -23,7x | -1,48 | 192,96 USD | 2,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
ICON PLC | NASDAQ | Salute | Ricerca medica e biotecnologica | 16,67 Mrd USD | 22,3x | 0,47 | 202,06 USD | 3,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 44,4% Rialzo | Fai l’upgrade a Pro+ | |
United Therapeutics | NASDAQ | Salute | Ricerca medica e biotecnologica | 16,28 Mrd USD | 15x | 0,58 | 364,75 USD | 1,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 6,9% Rialzo | Fai l’upgrade a Pro+ | |
Summit Therapeutics PLC | NASDAQ | Salute | Ricerca medica e biotecnologica | 14,75 Mrd USD | -68,5x | -0,92 | 19,27 USD | -3,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Moderna | NASDAQ | Salute | Ricerca medica e biotecnologica | 14,30 Mrd USD | -6,4x | -0,18 | 37,08 USD | -0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Genmab AS | NASDAQ | Salute | Ricerca medica e biotecnologica | 12,94 Mrd USD | 19,8x | 1,37 | 20,48 USD | -0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Insmed | NASDAQ | Salute | Ricerca medica e biotecnologica | 12,91 Mrd USD | -13x | 2,48 | 71,99 USD | -2,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 19,4% Rialzo | Fai l’upgrade a Pro+ | |
Neurocrine | NASDAQ | Salute | Ricerca medica e biotecnologica | 12,49 Mrd USD | 32x | 0,32 | 123,45 USD | 3,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 38,9% Rialzo | Fai l’upgrade a Pro+ | |
Bio-Techne | NASDAQ | Salute | Ricerca medica e biotecnologica | 10,81 Mrd USD | 71,3x | -1,9 | 68,05 USD | 2,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 28,1% Rialzo | Fai l’upgrade a Pro+ | |
Vaxcyte | NASDAQ | Salute | Ricerca medica e biotecnologica | 10,69 Mrd USD | -19,2x | 0,59 | 85,83 USD | -1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Sarepta | NASDAQ | Salute | Ricerca medica e biotecnologica | 10,46 Mrd USD | 87,1x | 0,71 | 109,70 USD | 2,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Medpace Holdings | NASDAQ | Salute | Ricerca medica e biotecnologica | 10,04 Mrd USD | 27,4x | 0,78 | 323,77 USD | 2,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 10,5% Rialzo | Fai l’upgrade a Pro+ | |
Exelixis | NASDAQ | Salute | Ricerca medica e biotecnologica | 9,84 Mrd USD | 21,8x | 0,05 | 34,42 USD | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -2,6% Ribasso | Fai l’upgrade a Pro+ | |
EXACT Sciences | NASDAQ | Salute | Ricerca medica e biotecnologica | 9,70 Mrd USD | -44,8x | -1,66 | 52,43 USD | -2,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 29,8% Rialzo | Fai l’upgrade a Pro+ | |
Revolution Med | NASDAQ | Salute | Ricerca medica e biotecnologica | 9,53 Mrd USD | -16x | 2,2 | 56,69 USD | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 24% Rialzo | Fai l’upgrade a Pro+ | |
Charles River Laboratories | NYSE | Salute | Ricerca medica e biotecnologica | 9,41 Mrd USD | 23x | -1,75 | 184,74 USD | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 18,2% Rialzo | Fai l’upgrade a Pro+ | |
Qiagen | NYSE | Salute | Ricerca medica e biotecnologica | 9,07 Mrd USD | 97,7x | -1,37 | 40,82 USD | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 22,5% Rialzo | Fai l’upgrade a Pro+ | |
Tempus AI | NASDAQ | Salute | Ricerca medica e biotecnologica | 8,50 Mrd USD | -9,1x | 0,11 | 58,13 USD | 7,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 3,8% Rialzo | Fai l’upgrade a Pro+ | |
WuXi Biologics | OTC Markets | Salute | Ricerca medica e biotecnologica | 8,02 Mrd USD | -1,21 | 1,86 USD | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Ascendis Pharma AS | NASDAQ | Salute | Ricerca medica e biotecnologica | 7,44 Mrd USD | -16x | -0,71 | 124,53 USD | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Legend Bio | NASDAQ | Salute | Ricerca medica e biotecnologica | 7,26 Mrd USD | -20,7x | -0,57 | 39,60 USD | 3,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Madrigal Pharma | NASDAQ | Salute | Ricerca medica e biotecnologica | 6,97 Mrd USD | -12,8x | 0,4 | 319,76 USD | 1,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 24,1% Rialzo | Fai l’upgrade a Pro+ | |
Nuvalent | NASDAQ | Salute | Ricerca medica e biotecnologica | 6,51 Mrd USD | -26,2x | 0,38 | 91,68 USD | 0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 23,5% Rialzo | Fai l’upgrade a Pro+ | |
Cytokinetics Inc | NASDAQ | Salute | Ricerca medica e biotecnologica | 5,95 Mrd USD | -9,4x | -3,94 | 50,17 USD | -1,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |